Camtek Ltd. filings document foreign-issuer current reports on operating results, customer orders, investor presentations, material agreements, capital structure and governance. The company’s Form 6-K disclosures include financial-result releases, order announcements for semiconductor inspection and metrology systems, and operating and financial review materials.
Camtek’s regulatory record also covers capital-structure activity, including convertible senior notes due 2030, and risk disclosures tied to semiconductor capital spending, demand for HPC, HBM and chiplet devices, global trade and export restrictions, and geographic concentration in Asia Pacific markets. These filings describe the company as a Nasdaq- and TASE-listed supplier serving IDMs, OSATs and foundries.
Camtek Ltd filed a notice for the potential sale of 3,296 Ordinary Shares through Oppenheimer & Co. Inc. on Nasdaq around 08/11/2026, with an aggregate market value of 521097.60 and 45828133 shares outstanding. The shares were acquired via RSU vestings of 9,738 shares on 01/16/2024, 5,564 on 02/15/2024, and 2,206 on 04/01/2025, each for no cash consideration.
A holder of Camtek Ltd. ordinary shares plans a potential sale of up to 3,347 shares through Oppenheimer & Co. Inc. on Nasdaq, with a proposed sale date of August 11, 2026. These shares were issued on June 1, 2026 upon vesting of RSUs for no cash consideration.
Phoenix Financial Ltd. reports beneficial ownership of 2,386,572.96 Camtek Ltd. ordinary shares, representing 5.12% of the class, based on 46,656,521 ordinary shares outstanding as of August 9, 2026. All voting and dispositive powers over these shares are shared, with no sole power reported.
As of August 6, 2026, the position was held across several Phoenix group entities, including trust funds, "nostro" accounts, pension and provident funds, linked insurance policies, and two partnerships whose ownership rights belong to Phoenix group companies. Phoenix and its subsidiaries state that each subsidiary operates under independent management and disclaims group status and beneficial ownership beyond actual pecuniary interest.
Camtek Ltd. reported record second-quarter 2026 revenue of $133.2 million, an 8% increase from $123.3 million a year earlier. GAAP gross profit was $66.7 million with a 50.1% gross margin, slightly below 50.8% in the prior-year quarter. GAAP operating income was $27.2 million (20.4% margin), down 15% from $32.0 million, mainly reflecting higher R&D and selling, general and administrative expenses. GAAP net income declined 31% to $23.3 million, or $0.46 per diluted share.
On a non-GAAP basis, gross profit was $68.5 million (51.4% margin) and operating income was $36.0 million (27.0% margin). Non-GAAP net income rose 2% to $39.4 million, or $0.78 per diluted share. Management cited acquisition-related expenses and a $7.7 million one-time tax expense among non-GAAP adjustments. Year-to-date orders exceeded $600 million, contributing to record backlog, and management expects Advanced Packaging revenue to grow about 70% between the first and fourth quarters of 2026.
Camtek guided third-quarter 2026 revenue to $158–$160 million, representing about a 20% sequential increase. It also expects more than 30% growth in second-half 2026 revenue versus first-half 2026, with continued growth into 2027. The balance sheet remains strong, with $815.8 million in cash, deposits and marketable securities as of June 30, 2026, against $488.5 million of convertible notes and total shareholders’ equity of $710.2 million.
Camtek Ltd director Shacham Yosef reported equity awards on July 29, 2026. He received 254 restricted stock units, each representing a contingent right to one ordinary share, and 571 stock options with a 147.87 per-share exercise price expiring July 29, 2033. Both awards vest at Camtek's 2027 annual shareholders meeting, and he now directly holds 6,734 ordinary shares plus 571 options.
Camtek Ltd director Andorn Karni Yarl reported equity-based compensation awards. He received 254 restricted stock units, each representing one Ordinary Share, vesting at the Company’s 2027 annual meeting of shareholders subject to continued service, and 571 stock options with a $147.87 exercise price, also vesting at that meeting and expiring on July 29, 2033. Following the RSU award, he directly owns 2,819 Ordinary Shares.
Stav Orit reported acquisition or exercise transactions in this Form 4 filing.
Camtek Ltd director Orit Stav received equity-based compensation consisting of 254 restricted stock units, each representing one ordinary share, and 571 stock options to buy ordinary shares at $147.8700 per share. Both the RSUs and options vest at the Company’s 2027 annual shareholder meeting, subject to continued service, and the options expire on July 29, 2033. After these awards, Stav is reported to hold 2,819 ordinary shares directly.
Camtek Ltd director Ben Arie Mordechay reported equity compensation awards dated July 29, 2026. He received 254 restricted stock units, each representing one ordinary share, and a grant of 571 stock options with a $147.8700 exercise price expiring on 2033-07-29. Both the RSUs and options vest on the date of the Company's 2027 annual meeting of shareholders, subject to his continued service.
Camtek Ltd., a foreign private issuer based in Israel, reported that it held an Annual General Meeting of Shareholders on July 29, 2026. All of the proposals presented to shareholders at this meeting were approved.
A proxy statement for the meeting had been filed with the U.S. Securities and Exchange Commission on June 24, 2026 as an exhibit to an earlier report and is incorporated by reference. The information from this meeting is also incorporated by reference into all of the company's effective registration statements under the Securities Act of 1933.
Migdal Insurance & Financial Holdings Ltd. and related entities report beneficial ownership of ordinary shares of Camtek Ltd. on an amended Schedule 13G. Migdal Insurance & Financial Holdings Ltd. has shared voting and dispositive power over 3,886,580 Camtek ordinary shares, representing 8.33% of the class, based on 46,656,521 shares outstanding as of July 8, 2026.
Within this total, Migdal Sal Domestic Equities has shared voting and dispositive power over 3,411,665 shares, representing 7.31% of the ordinary shares outstanding. The filing explains that various Migdal subsidiaries manage funds independently and that economic interests in these shares are largely held for insurance policy holders, fund members, and portfolio clients, with each filing person disclaiming beneficial ownership beyond its pecuniary interest.